4142:TPE
Adimmune Corp
16,15 NT$
arrow_downward
-0,62%(-0,10) 1D
18 ნოე, 13:30:02 GMT+8 · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
16,35 NT$
High
16,55 NT$
Low
16,00 NT$
Mkt. cap
6,94 მლრდ.
Avg. vol.
1,09 მლნ.
Volume
534,85 ათ.
52-wk high
21,50 NT$
52-wk low
15,65 NT$
EPS
-0,34 NT$
Shares outstanding
235,29 მლნ.
No. of employees
564
Open
16,35 NT$
High
16,55 NT$
Low
16,00 NT$
Mkt. cap
6,94 მლრდ.
Avg. vol.
1,09 მლნ.
Volume
534,85 ათ.
52-wk high
21,50 NT$
52-wk low
15,65 NT$
EPS
-0,34 NT$
Shares outstanding
235,29 მლნ.
No. of employees
564
News stories
From web sources and news partners
Benzinga
·
28 წუთის წინ
Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead of FOMC Minutes— NVDA, AAOI, PANW in Focus
MarketWatch
·
1 საათის წინ
The S&P 500 just broke a crucial support level. Here’s what history shows may happen now.
Investing.com
·
3 საათის წინ
The S&P 500 Is at a Crossroads as Nvidia Fails to Impress
www.tokenpost.com
·
1 საათის წინ
Nasdaq Gains 0.91% as S&P 500 Futures and Dow Also Advance
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp